Home

Cardionovum has announced the enrolment of the first patient in the international Hyper II clinical study designed to evaluate the safety and efficacy at 12 months of the hybrid treatment approach combining the Restore drug-coated balloon (DCB) with new a generation drug-eluting stent (DES) in long diffuse coronary artery disease (CAD).

The first procedure of the Hyper II clinical study was performed on 27 July at Sant’Ambrogio Cardio-Thoracic Center in Milan, Italy by Alfonso Ielasi, principal investigator of the study.

The Restore paclitaxel-coated balloon utilises a unique combination of a rapid absorption drug—paclitaxel—and patented Safepax, paclitaxel coating matrix.

The Hyper II is a prospective, non-randomised, multicentre clinical trial that will enrol up to 500 patients across 15 international sites and is built upon the findings of the Hyper Study presented at the EuroPCR 2022 (17–20 May, Paris, France), showing encouraging clinical results in terms of device-oriented composite endpoint (DoCE) of 3.7% at 12 months with no thrombosis reported in DES and DCB treated segments. The primary endpoint of the Hyper II study has been defined as the target lesion failure (TLF) incidence and will be assessed within 12 months after the index procedure.

“De novo diffuse coronary artery disease still represents an open issue in the field of interventional cardiology,” said Ielasi. “Overlapping DES and DCB in order to limit the total stent length may reduce the risks associated with permanent rigid metallic cages within the coronary wall. This concept could be particularly important in case of very long lesions involving small vessels and in diabetic patients.”

Miquel Craven-Bartle, Capella CEO of Cardionovum, commented: “Following our claim “Life deserves the best”, we are committed to improving patients’ quality of life by providing innovative solutions and clinical evidence for the treatment of cardiovascular disease. We are excited to announce the first procedure in the Hyper II trial and we truly hope that this trial will help generating a larger body of clinical evidence for a better treatment of patients with diffuse coronary artery disease.”

Chia sẽ qua facebook bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua google bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua twitter bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua MySpace bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua LinkedIn bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua stumbleupon bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua icio bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua digg bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Chia sẽ qua yahoo bài: First patient enrolled in Hyper II study evaluating hybrid approach in long diffuse CAD

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.